Wells Fargo raised the firm’s price target on CVS Health (CVS) to $73 from $68 and keeps an Overweight rating on the shares. The firm notes Q4 results were better than expected. Guidance for 2025 generally as expected with CVS emphasizing importance of setting targets it was confident it could deliver on. Wells continues to see optionality on faster Aetna margin recovery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Positive Outlook and Attractive Valuation Drive Buy Rating for CVS Health
- CVS Health price target raised to $73 from $71 at Barclays
- CVS Health: Strong Q4 Performance and Promising 2025 Outlook Justify Buy Rating
- Top Analysts Upgrade CVS Health Stock (CVS) after Upbeat Q4 Results
- CVS Health Reports Revenue Growth Amid Segment Challenges